glp 1 new drug GLP-1 Agonists: A Comprehensive Overview GLP-1 Medications for Weight Loss:

-Opportunity: Launch of GLP-1 biosimilars

These results are comparable to those observed in individuals receiving GLP-1R agonists and the co-agonists tirzepatide and retatrutide for the treatment of T2DM (Lorenz et al

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: A randomised, controlled, phase 1b trial

doi: 10.1530/acta.0.0440139

J.ChristopoulosA.et al (2011)

Borthwick Diabetes Research Centre, Lister Hospital, Coreys Mill Ln, Stevenage SG1 4AB, UK Tel: +44-1438-285972, Fax: +44-1438-284150, E-mail: [email protected] Copyright 2024 Korean Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited